Clinical Trials in New York

Showing 10101-10120 of 22,668 trials

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

NCT02323113

The purpose of the Phase 1b dose finding phase is to determine the safety, tolerability, and maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of TAK-659 in participants with relapsed or refractory AML. The purpose of the Phase 2 expansion phase is to evaluate preliminary efficacy of TAK-659 in relapsed or refractory AML as measured by overall response rate (ORR).

Acute Myelogenous Leukemia

Calithera Biosciences, Inc43 participantsStarted Mar 2015

Birmingham, Alabama, United States • Chicago, Illinois, United States • Niles, Illinois, United States +14 more locations

COMPLETEDPhase 2< 1 mile

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

NCT02049957

This is a phase 1b/2 study of the safety and efficacy of sapanisertib (MLN0128) in combination with exemestane or fulvestrant therapy in women with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced or metastatic breast cancer who progressed on treatment with everolimus in combination with exemestane or fulvestrant.

Breast Cancer

Calithera Biosciences, Inc118 participantsStarted Feb 2014

Los Angeles, California, United States • San Francisco, California, United States • Santa Barbara, California, United States +37 more locations

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Find Trials by Condition in New York

Feasibility of Light Therapy for Fatigue N-of-1 Trials

A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis

The Value of Home Chlorhexidine Pre-Surgical Wash Before Spine Surgery

Comparison Of Effective Radiation Shielding Between Rampart IC, M1128 Shield vs Conventional Apron And Shields In Clinical Interventional Procedures

Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants

SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence

Sargramostim Use in COVID-19 to Recover Patient Health

Corneal Collagen Crosslinking and Intacs for Keratoconus and Ectasia

Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19

Postoperative Activity Restrictions After Slings

ECG Belt for CRT Response

Validation of a Salivary miRNA Diagnostic Test for ASD

Improving Quality by Maintaining Accurate Problems in the EHR

A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis

A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis